Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

418 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.
Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, Chan TM, Hou FF, Lewis JB, Locatelli F, Praga M, Schena FP, Levey AS, Inker LA; Chronic Kidney Disease Epidemiology Collaboration. Heerspink HJL, et al. Among authors: praga m. Lancet Diabetes Endocrinol. 2019 Feb;7(2):128-139. doi: 10.1016/S2213-8587(18)30314-0. Epub 2019 Jan 8. Lancet Diabetes Endocrinol. 2019. PMID: 30635226
Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease.
de Vries AP, Ruggenenti P, Ruan XZ, Praga M, Cruzado JM, Bajema IM, D'Agati VD, Lamb HJ, Pongrac Barlovic D, Hojs R, Abbate M, Rodriquez R, Mogensen CE, Porrini E; ERA-EDTA Working Group Diabesity. de Vries AP, et al. Among authors: praga m. Lancet Diabetes Endocrinol. 2014 May;2(5):417-26. doi: 10.1016/S2213-8587(14)70065-8. Lancet Diabetes Endocrinol. 2014. PMID: 24795255 Review.
Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes.
Porrini E, Ruggenenti P, Mogensen CE, Barlovic DP, Praga M, Cruzado JM, Hojs R, Abbate M, de Vries AP; ERA-EDTA diabesity working group. Porrini E, et al. Among authors: praga m. Lancet Diabetes Endocrinol. 2015 May;3(5):382-91. doi: 10.1016/S2213-8587(15)00094-7. Lancet Diabetes Endocrinol. 2015. PMID: 25943757
Haematuria increases progression of advanced proteinuric kidney disease.
Yuste C, Rubio-Navarro A, Barraca D, Aragoncillo I, Vega A, Abad S, Santos A, Macias N, Mahillo I, Gutiérrez E, Praga M, Egido J, López-Gómez JM, Moreno JA. Yuste C, et al. Among authors: praga m. PLoS One. 2015 May 27;10(5):e0128575. doi: 10.1371/journal.pone.0128575. eCollection 2015. PLoS One. 2015. PMID: 26016848 Free PMC article.
Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis.
Inker LA, Mondal H, Greene T, Masaschi T, Locatelli F, Schena FP, Katafuchi R, Appel GB, Maes BD, Li PK, Praga M, Del Vecchio L, Andrulli S, Manno C, Gutierrez E, Mercer A, Carroll KJ, Schmid CH, Levey AS. Inker LA, et al. Among authors: praga m. Am J Kidney Dis. 2016 Sep;68(3):392-401. doi: 10.1053/j.ajkd.2016.02.042. Epub 2016 Mar 29. Am J Kidney Dis. 2016. PMID: 27032886
The Fatty Kidney: Obesity and Renal Disease.
Praga M, Morales E. Praga M, et al. Nephron. 2017;136(4):273-276. doi: 10.1159/000447674. Epub 2016 Jul 15. Nephron. 2017. PMID: 27414023 Review.
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
Fellström BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sørensen SS, Tesar V, Del Vecchio L; NEFIGAN Trial Investigators. Fellström BC, et al. Among authors: praga m. Lancet. 2017 May 27;389(10084):2117-2127. doi: 10.1016/S0140-6736(17)30550-0. Epub 2017 Mar 28. Lancet. 2017. PMID: 28363480 Free article. Clinical Trial.
Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update.
Coppo R, D'Arrigo G, Tripepi G, Russo ML, Roberts ISD, Bellur S, Cattran D, Cook TH, Feehally J, Tesar V, Maixnerova D, Peruzzi L, Amore A, Lundberg S, Di Palma AM, Gesualdo L, Emma F, Rollino C, Praga M, Biancone L, Pani A, Feriozzi S, Polci R, Barratt J, Del Vecchio L, Locatelli F, Pierucci A, Caliskan Y, Perkowska-Ptasinska A, Durlik M, Moggia E, Ballarin JC, Wetzels JFM, Goumenos D, Papasotiriou M, Galesic K, Toric L, Papagianni A, Stangou M, Benozzi L, Cusinato S, Berg U, Topaloglu R, Maggio M, Ots-Rosenberg M, D'Amico M, Geddes C, Balafa O, Quaglia M, Cravero R, Lino Cirami C, Fellstrom B, Floege J, Egido J, Mallamaci F, Zoccali C; ERA-EDTA Immunonephrology Working Group. Coppo R, et al. Among authors: praga m. Nephrol Dial Transplant. 2020 Jun 1;35(6):1002-1009. doi: 10.1093/ndt/gfy302. Nephrol Dial Transplant. 2020. PMID: 30418652
418 results